Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at UBS Group from a “sell” rating to a ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...

Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...

First Hawaiian Bank boosted its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 30.3% in the fourth ...

but this miss means little to Novo Nordisk's long-term prospects. Further, the company has several exciting candidates in other areas, including rare diseases and neurological conditions such as ...